Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCGI0283


Novel Gastrointestinal Cancer Markers in Tissue and Biofluids

Principal Investigator(s)

Robert Beauchamp


  • Protocol No. VICCGI0283
  • Open Date: 06/01/2002
  • Staging: N/A
  • Age Group: Adults
  • Scope: Local
  • Objective: NMCC-identifies substances called candidate markers in stool, blood, tumor tissue and normal colon mucosa to detect colon cancer.
  • Disease Sites: Gastrointestinal
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Veterans Administration; Vanderbilt University
  • National Clinical Trial ID: NCT00899626
  • Secondary Protocol No: Not Specified


Patients are being asked to participate in this study because they have a diagnosis of a precancerous gastrointestinal condition, cancer or inflammatory bowel disease. This is a common disease that may be cured or better understood if detected early. One way to do this may be to identify substances called caididate markers in tissue, blood, and urine.


Ages Eligible for Study:18 Years and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:Accepts Healthy Volunteers


• Meets 1 of the following criteria:
• Diagnosis of gastrointestinal (GI) cancer, polyps, or inflammatory bowel disease
• History of previously treated GI cancer, polyps, or inflammatory bowel disease
• Healthy volunteer
• Undergoing colonoscopy or endoscopy for diagnostic or screening purposes at the Vanderbilt University Medical Center or at the Veterans Affairs Medical Center
• Hemoglobin ≥ 8.0 g/dL
• Not pregnant
• Fertile participants must use effective contraception
• Capable of giving informed consent
• Not mentally or medically impaired
• No bleeding disorder
• See Disease Characteristics